<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230659</url>
  </required_header>
  <id_info>
    <org_study_id>IC/CLS6</org_study_id>
    <nct_id>NCT00230659</nct_id>
  </id_info>
  <brief_title>Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia</brief_title>
  <official_title>Investigation of Coagulation Parameters in Hereditary Haemorrhagic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hammersmith Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <brief_summary>
    <textblock>
      The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from
      dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop
      deep venous thromboses and/or pulmonary embolism, necessitating treatments with
      anticoagulants that further impair control of their haemorrhagic state. Our initial
      observations using general coagulation tests suggest that the blood of HHT patients is
      intrinsically hypercoagulable.

      We hypothesize that the genetically-determined abnormality in the blood vessels of HHT
      patients leads to alteration in the concentrations or activity of one or several of the
      proteins which affect blood clotting leading to a hypercoagulable state.

      We propose to study levels and activity of blood coagulation factors in people with
      hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the
      significance and basis for our initial observations, and will have significant implications
      for the clinical management of HHT patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment>100</enrollment>
  <condition>Telangiectasia, Hereditary Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>HHT patients</arm_group_label>
    <description>Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample to be taken.</intervention_name>
    <description>Blood sample to be taken.</description>
    <arm_group_label>HHT patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HHT and normal controls

        Exclusion Criteria:

          -  Previous thrombosis, recent ill health
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Shovlin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Hammersmith Campus</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007 Nov;98(5):1031-9.</citation>
    <PMID>18000608</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2005</study_first_submitted>
  <study_first_submitted_qc>September 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2005</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

